Potential role of platelet glycoprotein IIb/IIIa antagonists in cerebrovascular disorders

Studies have confirmed the benefit of established antiplatelet therapies [a spirin (acetylsalicylic acid), clopidogrel, or a combination of aspirin and dipyridamole] in cerebrovascular disorders such as stroke. Recent data ind icate that glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonist antiplate let agents (which are currently marketed or are being investigated for thei r efficacy in cardiovascular indications) may also be beneficial in patient s who have had a stroke. These agents may have potential value as monothera py or as adjuncts to thrombolytics or interventional procedures. However, G PIIb/IIIa antagonists carry a risk of cerebral haemorrhage, which may be hi gher in patients with acute stroke than in patients with transient ischaemi c attack or partial occlusion.